328 related articles for article (PubMed ID: 32654802)
1. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
Rini BI; Motzer RJ; Powles T; McDermott DF; Escudier B; Donskov F; Hawkins R; Bracarda S; Bedke J; De Giorgi U; Porta C; Ravaud A; Parnis F; Grande E; Zhang W; Huseni M; Carroll S; Sufan R; Schiff C; Atkins MB
Eur Urol; 2021 May; 79(5):659-662. PubMed ID: 32654802
[TBL] [Abstract][Full Text] [Related]
2. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab
Atkins MB; Rini BI; Motzer RJ; Powles T; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Gurney H; Oudard S; Uemura M; Lam ET; Grüllich C; Quach C; Carroll S; Ding B; Zhu QC; Piault-Louis E; Schiff C; Escudier B
Clin Cancer Res; 2020 Jun; 26(11):2506-2514. PubMed ID: 32127394
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Pal SK; McDermott DF; Atkins MB; Escudier B; Rini BI; Motzer RJ; Fong L; Joseph RW; Oudard S; Ravaud A; Bracarda S; Suárez C; Lam ET; Choueiri TK; Ding B; Quach C; Hashimoto K; Schiff C; Piault-Louis E; Powles T
BJU Int; 2020 Jul; 126(1):73-82. PubMed ID: 32233107
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Powles T; Atkins MB; Escudier B; Motzer RJ; Rini BI; Fong L; Joseph RW; Pal SK; Sznol M; Hainsworth J; Stadler WM; Hutson TE; Ravaud A; Bracarda S; Suarez C; Choueiri TK; Reeves J; Cohn A; Ding B; Leng N; Hashimoto K; Huseni M; Schiff C; McDermott DF
Eur Urol; 2021 May; 79(5):665-673. PubMed ID: 33678522
[TBL] [Abstract][Full Text] [Related]
7. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF; Huseni MA; Atkins MB; Motzer RJ; Rini BI; Escudier B; Fong L; Joseph RW; Pal SK; Reeves JA; Sznol M; Hainsworth J; Rathmell WK; Stadler WM; Hutson T; Gore ME; Ravaud A; Bracarda S; Suárez C; Danielli R; Gruenwald V; Choueiri TK; Nickles D; Jhunjhunwala S; Piault-Louis E; Thobhani A; Qiu J; Chen DS; Hegde PS; Schiff C; Fine GD; Powles T
Nat Med; 2018 Jun; 24(6):749-757. PubMed ID: 29867230
[TBL] [Abstract][Full Text] [Related]
10. Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404-15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma.
Singla N
Eur Urol; 2020 Jun; 77(6):e168-e169. PubMed ID: 31676127
[No Abstract] [Full Text] [Related]
11. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
17. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
Klümper N; Cox A; Eckstein M; Kuppe C; Ritter M; Brossart P; Luetkens J; Hölzel M; Stein J; Saal J
Eur J Cancer; 2024 Jun; 204():114089. PubMed ID: 38703618
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
19. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
20. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
